Medtronic Plc (MDT)

In the past six months, Medtronic's stock price increased by 9.29% from June 28, 2024. The stock was up 4.10% over the past 30 days and 13.03% over the past 12 months as of June 30, 2025. Medtronic's cardiovascular portfolio demonstrated mid-single-digit growth in fiscal Q3 2025, with its Cardiac Ablation Solutions business growing by 22%. The company received FDA approval for its newest generation Evolut TAVR system and released new data from the TVAR trial. The Aurora Extravascular ICD received FDA approval and CE Mark. Medtronic announced its intention to separate its Diabetes business into a new standalone company named MiniMed. Medtronic's Board appointed Dr. Joon Lee as a new director. The company's net sales climbed to $33.5 billion in 2025, and net income increased to $4.7 billion. Medtronic's earnings have surpassed estimates in each of the trailing four quarters.

Information regarding the specific demand seasonality for Medtronic Plc's products and services was not found in the provided search results. The available information primarily pertains to stock price seasonality, which indicates tools exist to analyze monthly stock performance patterns.

Medtronic Plc is a global leader in medical technology, specializing in therapeutic medical devices for chronic diseases. Its product portfolio is organized into four main business units: Cardiovascular Portfolio, which includes devices for heart rhythm disorders and cardiovascular diseases; Neuroscience Portfolio, which focuses on cranial and spinal technologies; Medical Surgical Portfolio, which provides surgical innovations; and Diabetes Operating Unit, which offers insulin pumps and continuous glucose monitoring systems.

Medtronic has a significant global presence, operating in over 150 countries. Its legal and executive headquarters are in Galway, Ireland, while its operational headquarters are in Minneapolis, Minnesota, U.S. The company primarily markets its products in the United States, Western Europe, and Japan, with foreign sales accounting for approximately 50% of its total sales. Medtronic is actively expanding in emerging markets, with operations categorized into Ireland, the United States, and the Rest of the World.

Medtronic has a strong brand reputation due to its high-quality, innovative medical devices. The company's financial performance and investments in research and development further reinforce its brand standing. No specific negative events significantly impacting Medtronic's brand reputation in the past year were identified.

Medtronic's ownership is predominantly institutional, with institutional investors holding a significant portion of the stock. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., and State Street Corp. Individual investors hold a smaller portion, and insiders own approximately 0.07% of the company's stock.